Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 1917570, 8 pages
https://doi.org/10.1155/2017/1917570
Clinical Study

Efficacy and Tolerability of Travoprost 0.004/Timolol 0.5 Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

1Organización Medica de Investigación (OMI), Buenos Aires, Argentina
2Fundación para el Estudio del Glaucoma, Buenos Aires, Argentina
3Seoul National University Hospital, Seoul, Republic of Korea
4Alcon Research, Ltd., Fort Worth, TX, USA
5Research Institute of Eye Diseases, Moscow, Russia
6Instituto de Oftalmologia y Ciencias Visuales, CUCS, Universidad de Guadalajara, Guadalajara, JAL, Mexico
7Unidad de Diagnostico Temprano del Glaucoma, Global Glaucoma Institute Occidente, Guadalajara, JAL, Mexico
8Sydney Medical School, University of Sydney, Sydney, NSW, Australia
9Vision Eye Institute, Sydney, NSW, Australia

Correspondence should be addressed to Simon Fabian Lerner; ra.moc.oohay@samocualg

Received 21 September 2016; Revised 13 December 2016; Accepted 29 December 2016; Published 23 January 2017

Academic Editor: Tamer A. Macky

Copyright © 2017 Simon Fabian Lerner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Terminology and Guidelines for Glaucoma, European Glaucoma Society, 4th edition, 2014, http://www.icoph.org/dynamic/attachments/resources/egs_guidelines_4_english.pdf.
  2. A. Bagnis, M. Papadia, R. Scotto, and C. E. Traverso, “Current and emerging medical therapies in the treatment of glaucoma,” Expert Opinion on Emerging Drugs, vol. 16, no. 2, pp. 293–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Vass, C. Hirn, T. Sycha, O. Findl, P. Bauer, and L. Schmetterer, “Medical interventions for primary open angle glaucoma and ocular hypertension,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003167, 2007. View at Google Scholar · View at Scopus
  4. Collaborative Normal-Tension Glaucoma Study Group, “The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma,” American Journal of Ophthalmology, vol. 126, no. 4, pp. 498–505, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, and M. Hussein, “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1268–1279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Kass, D. K. Heuer, E. J. Higginbotham et al., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma,” Archives of Ophthalmology, vol. 120, no. 6, pp. 701–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Leske, S.-Y. Wu, A. Hennis, R. Honkanen, and B. Nemesure, “Risk factors for incident open-angle glaucoma: the Barbados Eye Studies,” Ophthalmology, vol. 115, no. 1, pp. 85–93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. R. Lichter, D. C. Musch, B. W. Gillespie et al., “Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery,” Ophthalmology, vol. 108, no. 11, pp. 1943–1953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman, and E. Komaroff, “Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial,” Archives of Ophthalmology, vol. 121, no. 1, pp. 48–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. E. Prum, L. F. Rosenberg, S. J. Gedde et al., “Primary open-angle glaucoma,” Ophthalmology, vol. 123, no. 1, pp. P41–P111, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. R. L. Stamper, S. A. Wigginton, and E. J. Higginbotham, “Primary drug treatment for glaucoma: beta-blockers versus other medications,” Survey of Ophthalmology, vol. 47, no. 1, pp. 63–67, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. H. S. Barnebey, S. Orengo-Nania, B. E. Flowers et al., “The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution,” American Journal of Ophthalmology, vol. 140, no. 1, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. S. Schuman, G. J. Katz, R. A. Lewis et al., “Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension,” American Journal of Ophthalmology, vol. 140, no. 2, pp. 242.e1–242.e11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Noecker, N. S. Awadallah, and M. Y. Kahook, “Travoprost 0.004%/timolol 0.5% fixed combination,” Drugs of Today, vol. 43, no. 2, pp. 77–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K.-O. Arend and T. Raber, “Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany,” Journal of Ocular Pharmacology and Therapeutics, vol. 24, no. 4, pp. 414–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Mandić, K. Novak-Laus, and L. Bojić, “Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period,” Acta Clinica Croatica, vol. 49, pp. 411–419, 2010. View at Google Scholar
  17. N. Pfeiffer, M.-L. Scherzer, H. Maier et al., “Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy,” Clinical Ophthalmology, vol. 4, no. 1, pp. 459–466, 2010. View at Google Scholar · View at Scopus
  18. G. Hoxha, K. Spahiu, G. Kaçaniku, F. Ismajli-Hoxha, and M. Ismaili, “Comparison of prostaglandin analogue, beta-blockers and prostaglandin analogue/beta-blockers fixed combination in patients with primary open-angle glaucoma,” Spektrum der Augenheilkunde, vol. 27, no. 5, pp. 239–244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kitazawa, P. Smith, N. Sasaki, S. Kotake, K. Bae, and Y. Iwamoto, “Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy,” Eye, vol. 25, no. 9, pp. 1161–1169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. da Silva Jordão, M. Hatanaka, A. Ogundele, M. R. B. De Moraes Silva, and R. M. Vessani, “Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy,” Clinical Ophthalmology, vol. 8, pp. 1527–1534, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. V. P. Costa, H. Moreira, M. D. Paolera, and M. R. B. D. M. Silva, “Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy,” Clinical Ophthalmology, vol. 6, no. 1, pp. 699–706, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Topouzis, S. Melamed, H. Danesh-Meyer et al., “A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension,” European Journal of Ophthalmology, vol. 17, no. 2, pp. 183–190, 2007. View at Google Scholar · View at Scopus
  23. L. Quaranta, E. Biagioli, I. Riva et al., “Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis,” Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 4, pp. 382–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-W. Cheng, S.-W. Cheng, L.-D. Gao, G.-C. Lu, and R.-L. Wei, “Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis,” PLoS ONE, vol. 7, no. 9, Article ID e45079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. E. J. Higginbotham, “Considerations in glaucoma therapy: fixed combinations versus their component medications,” Clinical Ophthalmology, vol. 4, no. 1, pp. 1–9, 2010. View at Google Scholar · View at Scopus